Struma ovarii natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
Line 4: Line 4:
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}}  
==Overview==
==Overview==
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
If left untreated Struma ovarii may lead to thyrotoxicosis
*Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
*Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==



Revision as of 12:24, 22 August 2017

Struma ovarii Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Struma ovarii from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

ECG

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Struma ovarii natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Struma ovarii natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Struma ovarii natural history, complications and prognosis

CDC on Struma ovarii natural history, complications and prognosis

Struma ovarii natural history, complications and prognosis in the news

Blogs on Struma ovarii natural history, complications and prognosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Struma ovarii natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

If left untreated Struma ovarii may lead to thyrotoxicosis

  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

Natural History, Complications, and Prognosis

Natural History

  • If left untreated Struma ovarii may lead to thyrotoxicosis [1]
  • Advanced disease may lead to malignancy, metastases, excessive hormone production and may prove fatal. [2]

Complications

  • The most feared complication of struma ovarii is thyrotoxicosis. Other complications include due to metastasis of stroma oavrii.[3]

Prognosis

  • Prognosis is generally excellent under benign conditions and in malignant cases, adjuvant iodine-131 ablation with surgical extirpation has excellent prognosis
  • The 5/10/20-year mortality/survival rate of patients with Struma ovarii is approximately 96.7%, 94.3%, and 84.9%, respectively.
  • In adults with differentiated thyroid cancer who are treated with high doses of radioiodine seem to have an excellent long-term prognosis. [4]

References

  1. Morrissey K, Winkel C, Hild S, Premkumar A, Stratton P (2007). "Struma ovarii coincident with Hashimoto's thyroiditis: an unusual cause of hyperthyroidism". Fertil. Steril. 88 (2): 497.e15–7. doi:10.1016/j.fertnstert.2006.11.095. PMC 2753978. PMID 17276434.
  2. Colomo Rodríguez, Natalia; Ruiz De Adana Navas, M. Soledad; González Romero, Stella; González Molero, Inmaculada; Reguera Iglesias, José M. (2011). "Leishmaniasis visceral en un paciente con diabetes tipo 1 y trasplante aislado de páncreas". Endocrinología y Nutrición. 58 (7): 375–377. doi:10.1016/j.endonu.2011.02.004. ISSN 1575-0922.
  3. Matsuda K, Maehama T, Kanazawa K (2001). "Malignant struma ovarii with thyrotoxicosis". Gynecol. Oncol. 82 (3): 575–7. doi:10.1006/gyno.2001.6315. PMID 11520159.
  4. Luo JR, Xie CB, Li ZH (2014). "Treatment for malignant struma ovarii in the eyes of thyroid surgeons: a case report and study of Chinese cases reported in the literature". Medicine (Baltimore). 93 (26): e147. doi:10.1097/MD.0000000000000147. PMC 4616397. PMID 25474425.

Template:WH Template:WS